Healthcare [ 13/13 ] | Biotechnology [ 106/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 14, 24 | -0.13 Increased by +45.83% | -0.05 Decreased by -160% |
| Nov 7, 23 | -0.16 Increased by +15.79% | -0.19 Increased by +15.79% |
| Aug 8, 23 | -0.2 Decreased by -17.65% | -0.2 |
| May 9, 23 | -0.22 Decreased by -15.79% | -0.21 Decreased by -4.76% |
| Mar 14, 23 | -0.24 Increased by +7.69% | -0.22 Decreased by -9.09% |
| Nov 8, 22 | -0.19 Decreased by -127.54% | -0.19 |
| Aug 9, 22 | -0.17 Increased by +54.05% | -0.23 Increased by +26.09% |
| May 10, 22 | -0.19 Increased by +29.63% | -0.3 Increased by +36.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 83.8 M Increased by +195.22% | -46.29 M Increased by +52.47% | Decreased by -55.24% Increased by +83.9% |
| Sep 30, 23 | 24.31 M Increased by +6.77% | -62.2 M Increased by +16.26% | Decreased by -255.82% Increased by +21.57% |
| Jun 30, 23 | 25.3 M Increased by +20.88% | -73.43 M Decreased by -43.69% | Decreased by -290.28% Decreased by -18.86% |
| Mar 31, 23 | 22.9 M Decreased by -11.72% | -67.85 M Decreased by -6.9% | Decreased by -296.25% Decreased by -21.09% |
| Dec 31, 22 | 28.39 M Increased by +40.1% | -97.4 M Decreased by -48.67% | Decreased by -343.12% Decreased by -6.12% |
| Sep 30, 22 | 22.77 M Decreased by -91% | -74.28 M Decreased by -141.6% | Decreased by -326.18% Decreased by -562.1% |
| Jun 30, 22 | 20.93 M Increased by +95.02% | -51.1 M Increased by +38.64% | Decreased by -244.21% Increased by +68.54% |
| Mar 31, 22 | 25.94 M Increased by +121.36% | -63.47 M Decreased by -18.24% | Decreased by -244.66% Increased by +46.58% |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.